Multiple Sclerosis (MS) is a long-lasting (chronic) autoimmune disease due to a damage on the myelin of nerve cells in the brain and spinal cord. This damage disrupts the ability of parts of the nervous system to transmit signals, resulting in a range of symptoms including physical, mental and psychiatric problems. While the cause of MS is unclear, it is known that effector T cells attack myelinated axons in the central nervous system.
Treg therapy has been used in clinical trials for patients with Crohn’s Disease, Type I Diabetes, Lupus, and autoimmune hepatitis. Regarding Treg cells suppression of autoreactive T cells naturally without adverse problems, Treg therapy has been suggested as the next alternative therapeutic option in Multiple Sclerosis (MS). Currently, there are limitations to using Treg transfer therapy for MS. One major issue is that Treg cells in patients with MS are often less suppressive than healthy donors.
TeraImmune is dedicated to the development of Treg therapy specific to MS (Pipeline TI-235). Our team has successfully demonstrated the therapeutic potential of MS TCR-Treg in vitro and in a mouse model (Experimental Autoimmune Encephalomyelitis model). TeraImmune is now developing Standard Operating Procedures to produce clinical-grade MS TCR-Tregs using the patient’s own Treg cells.